Free Legal Shield

Speak with us

(800) 733-5342
Menu

Al

Dow breast implant lawyers are still accepting clients

Written by

If you have filed a breast implant claim prior to 1994 a breast implant lawyer may be able to help you with your breast implant settlement.

Breast Implant Helpline Accepting Clients for Dow Corning Claims
Breast Implant Helpline ,breast Implant lawyers announces a new female lawyer as part of the network to accept Dow Corning Breast Implant claims. If you have received a rejection notice from a law office contact us for a Breast Implant Claim Review

FOR IMMEDIATE RELEASE

PRLog (Press Release) Apr 21, 2012 Breast Implant Helpline and Breast Implant Lawyers are accepting cases for the Dow Corning Trust Breast Implant Claims. We are helping 1000′s of women with unsettled claims or who have rejection letters from other law firms. http://breastimplanthelpline.com/breast-implant-helpline-

Contact the Breast Implant Claim Helpline and Speak to a female Medical Social Worker about your breast Implant Claim and Complications. http://breastimplanthelpline.com/get-a-lawyer/ We will help you locate a female breast Implant Lawyer. The breast implant Helpline is supporting and assisting women breast Implant victims nationwide. If you need help with Breast Implant Litigation Cases dealing with the Settlement Facility-Dow Corning Trust (SF-DCT) or the Revised Settlement Plant (RSP) – MDL-926 Claims Office contact the breast Implant lawyers of the Breast Implant Helpline and speak to our female medical social worker today. We are here to assist women with legal issues regarding their Dow claims for implants prior to 1994. Call 1 877 522-2123 for help about your breast implant claim.

If you are a victim of silicone breast implants or have filed a claim and have a notice of deficiency or a rejection letter from a law firm we want to hear from you
Silicone breast Implant toxicity Complications Include:

  • dry eyes
  • joint pain and swelling
  • myalgias
  • chronic fatigue
  • Lupus
  • numbness and tingling in extremities
  • photosensitivity
  • Chemical Sensitivities
  • Muscle Pain, Stiffness, Unusual Fatigue
  • Excessive Hair Loss
  • Achy or Swollen Joints
  • Extreme fatigue
  • Skin Rashes
  • Rheumatoid Arthritis
  • Polymyositis-Dermatomyositis
  • Mixed Connective Tissue Disease
  • Scleroderma
  • Sjogren s syndrome
  • Anemia
  • Sensitivity to Sunlight
  • Kidney Problems
  • Fever
  • Difficulty Swallowing or Breathing

Breast Implant complications may be serious. You must see a physician immediately.

Symptoms of Lupus

  • Fatigue and fever
  • Joint pain, stiffness and swelling
  • Butterfly-shaped rash on the face that covers the cheeks and bridge of the nose
  • Skin lesions that appear or worsen with sun exposure
  • Fingers and toes that turn white or blue when exposed to cold or during stressful periods (Raynaud s phenomenon)
  • Shortness of breath
  • Chest pain
  • Dry eyes
  • Headaches, confusion, memory loss

If you have a claim filed under the Breast implant settlement claims help is here for you.

Bayer Settles on Yaz, Opens Door to Yaz Lawsuits

Written by

The Yaz Helpline and Yaz Lawyers are pleased to announce Bayer, has agreed to pay out at least $110 million to settle 500 lawsuits involving Yaz blood clots. News of the settlements comes at a time when the Yaz lawsuit total exceeds 11,000, with plaintiffs claiming the birth control pill resulted in dangerous Yaz blood clots

In addition to the Yaz settlements the Food and Drug Administration has placed new warnings on Yaz packaging du to numerus studies showing a link between Yaz and blood clots, stroke and pulminery embolism. This new warning comes as a reiied to medical practitioners who are prescribing Yaz. and have been concerned about the impact of Yaz side effects. Thousands of women affected by Yaz side effects including Yaz deep vein thrombosis and Yaz gallbladder disease have filed suit against drug maker Bayer. In light of the new warnings and settlement offers Yaz lawyers are accepting cases for yaz.

Yaz Hotline is here to help women harmed by yaz. Call and Speak to a female Social Worker and be connected to a yaz lawyer

Women s Yaz Hotline Launch is based on a recently issued FDA Warning for the drugs YAZ,Yasmin and Ocella.MDL lawsuits for Yaz,Yasmin are currently being filed. If you have experienced complications with Yaz,Yasmin or ocella,call the a Yaz, Ocella,Yasmin Lawyer Hotline Attorney today. The hotline is here for you 24/71 877 522 2123 You will speak to a medical social worker.
The Federal/State Yaz, Yasmin, Birth Control Lawsuits are being filed by Yaz Lawyers. The Yaz, Yasmine Hotline is here to answer your questions and connect you with a YAZ, Yasmin or Ocella lawyer.Referencing the New York Times," Yaz has been one of the top-selling birth control pills in the U.S and Canada., with nearly 20 percent of the market. In 2008, more than $600 million dollars worth of Yaz was sold in the U.S. However, the television commercials advertising Yaz were of concern to the FDA and the Attorney General because they implied that Yaz could be used to treat or cure symptoms for which it was not FDA-approved, such as:

  • Keeping a woman s mild acne at bay
  • Relieving symptoms of PMS (premenstrual syndrome):
  • irritability
  • increased appetite
  • moodiness
  • fatigue
  • headaches
  • bloating
  • muscle aches

Bayer agreed to make new commercials and print advertisements that did not promise more for Yaz than had been approved by the FDA, and that did not minimize the risks of Yaz birth control pills, which are many. Yaz is FDA-approved only for:
preventing pregnancy
treating the symptoms of PMDD (premenstrual dysphoric disorder) in women who are using Yaz as their contraceptive
treating moderate acne vulgaris in women who are using Yaz to prevent pregnancy
Safety Announcement
[09-26-2011] The U.S. Food and Drug Administration (FDA) is informing the public that it has not yet reached a conclusion, but remains concerned, about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills. FDA has completed its review of the two 2011 studies that evaluated the risk of blood clots for women who use drospirenone-containing birth control pills, previously mentioned in FDA s Drug Safety Communication issued on May 31, 2011. FDA is continuing its review of a separate FDA-funded study that evaluated the risk of blood clots in users of several different hormonal birth control products (contraceptives). Preliminary results of the FDA-funded study suggest an approximately 1.5-fold increase in the risk of blood clots for women who use drospirenone-containing birth control pills compared to users of other hormonal contraceptives.
Given the conflicting nature of the findings from six published studies evaluating this risk, as well as the preliminary data from the FDA-funded study (See Data Summary), FDA has scheduled a joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on December 8, 2011 to discuss the risks and benefits and specifically the risk of blood clots of drospirenone-containing birth control pills.

Patients should talk to their healthcare professional about their risk for blood clots before deciding which birth control pill to use. Known risk factors that increase the risk of a blood clot include smoking, being overweight (obesity), and family history of blood clots, in addition to other factors that contraindicate use of birth control pills.
Women currently taking a drospirenone-containing birth control pill should be informed of the potential risk for blood clots. FDA previously communicated preliminary information about these concerns to the public on May 31, 2011 .
FDA has prepared a list of questions and answers to provide an overview of this potential safety issue. FDA will continue to communicate any new information to the public as it becomes available
Health Canada is currently reviewing the safety of Bayer Pharmaceutical’s birth control pills, Yaz and Yasmin, in an effort to determine if women who use these drugs are at an increased risk of developing life-threatening blood clots over women using different brands of birth control.

Yaz Lawyers of Free Legal Shield are pleased to announce that contraceptive Manufacturer, Bayer, has agreed to pay out at least $110 million to settle 500 lawsuits involving Yaz blood clots. News of the settlements comes at a time when the Yaz lawsuit total exceeds 11,000, with plaintiffs claiming the birth control pill resulted in dangerous blood clots.

New Warning Labels on Yaz April 2012

In an announcement released April 10, 2012, the FDA stated that new warnings about the risk of blood clots will now be required on the labels of birth control pills that contain the progestin “drospirenone.” Yaz, Yasmin, Beyaz, and Safyral will now carry warnings detailing recent studies that suggest these pills may carry a slightly higher risk of Yaz blood clots.

Many Studies show Yaz linked to Blood Clots

two new studies recently published in the British Medical Journal, which concluded that women ages 15-44 taking birth control pills containing the synthetic progestin, drospirenone, are more likely to develop blood clots deep in the veins of the leg (venous thromboembolism), than women using birth control pills containing the common progestin levonorgestrel. The studies reported that the risk of developing blood clots for women taking the drospirenone-containing pills may be two to three times greater than those who take other pills. Yaz is one of these drugs.

Yaz New Warnings April 2012

In an announcement released April 10, 2012, the FDA stated that new warnings about the risk of blood clots will now be required on the labels of birth control pills that contain the progestin “drospirenone.” Yaz, Yasmin, Beyaz, and Safyral will now carry warnings detailing recent studies that suggest these pills may carry a slightly higher risk of Yaz blood clots

Yaz side effects include:
• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Blood clots
• Stroke
• Heart attack
• Gallbladder problems
• Pancreatitis
List of Drugs
Approved Oral Contraceptives containing Drospirenone

  • Drospirenone and ethinyl estradiol Drospirenone 3 mg and ethinyl estradiol 0.03 mg
  • Ocella Drospirenone 3 mg and ethinyl estradiol 0.03 mg
  • Safyral Drospirenone 3 mg, ethinyl estradiol 0.03 mg, and levomefolate calcium 0.451 mg
  • Syeda Drospirenone 3 mg and ethinyl estradiol 0.03 mg
  • Yasmin Drospirenone 3 mg and ethinyl estradiol 0.03 mg
  • Zarah Drospirenone 3 mg and ethinyl estradiol 0.03 mg
  • Beyaz Drospirenone 3 mg, ethinyl estradiol 0.02 mg and levomefolate calcium 0.451 mg
  • Drospirenone and ethinyl estradiol Drospirenone 3 mg and ethinyl estradiol 0.02 mg
  • Gianvi Drospirenone 3 mg and ethinyl estradiol 0.02 mg
  • Loryna Drospirenone 3 mg and ethinyl estradiol 0.02 mg
  • Yaz Drospirenone 3 mg and ethinyl estradiol 0.02 mg

Recent warnings have linked various birth control drugs and devices to serious injuries and even death:

  • Yasmin®
  • Yaz®
  • Ocella®

Injuries reported:

  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Stroke
  • Heart Attack
  • Wrongful Death
  • Blood Clot Related Injuries
  • Kidney Failure
  • Gallbladder Injury/Removal

If you or a loved one has suffered from any of the harmful side effects of Yaz,Yasmin or Ocella such as blood clots, stroke or heart attack you may be entitled to file a Yaz,Yasmin,Ocella lawsuit against the manufacturer. Call us for a yaz lawyer with experience in birth control drug lawsuits toevaluate your claim. Many women around the United States have suffered from life-threatening Yaz,Ocella and Yasmin birth control side effects. The manufacturer can be held liable.
The Woman s Yaz Hotline is here for women suffering from Yasmin and Yaz and Drospirenone side effects

Vaginal Mesh a Disaster for Women, Lawyers filing lawsuits

Written by

If you have a vaginal mesh and are experiencing complications you need to find a Urogynecologist and you must get a Vaginal mesh lawyer.

Ask Questions and Get Answers. You are not alone and you are not imagining it. Over 300,000 women have vaginal mesh implants. They are failing in women across the country and lawsuits are being filed. Ask Qustions and get answers. These are not class Action litigations. They are multi district litigations. That means they are consolidated in certain states in certain courtrooms under one judge and that may not be the state you are in. You need an experienced mass tort lawyer who will be appearing in court for you as a part of this multi district litigation. These are not class actions. You will have your case filed on an individual basis as an MDL. Ask quesions and get answers. You do not need a local lawyer. You do need a lawyer that is keeping your case and not referring it out to another lawyer to go to court for him. Ask Questions and get answers. Choose your vaginal Mesh lawyer wisely.

What is the Vaginal Mesh?

Also known as a pelvic sling, bladder mesh, or transvaginal mesh, the vaginal mesh support systems are used to help with pelvic organ prolapse as well as urinary incontinence It is now known that they can cause serious internal injuries. These vaginal mesh patch implants, manufactured by Johnson & Johnson , C.R. Bard, Boston Scientific, American Medical Systems, and others, may cause pain, infection, erosion, organ damage, and additional surgeries, and other vaginal mesh injuries.

If you have experienced vaginal mesh complications following pelvic organ prolapse surgery or stress urinary incontinence surgery, The vaginal mesh support line will offer help and direct you to a lawyer who may be able to help you obtain significant compensation for the vaginal mesh problems you are experiencing.

Ask questions and get answers

Call us at 1 877 -522-2123 to speak with a female social worker and be directed to a lawyer.

Vaginal Mesh- History of the Problem

Between the years of 2005 and 2010, nearly 4,000 vaginal mesh injuries have been reported to the Food and Drug Administration. In a 2010 article in the journal Obstetrics & Gynecology, researchers stated that they had to cease a vaginal mesh clinical trial early because of the higher-than-expected number of complications and injuries. The trial was stopped when it was discovered that more than 15 percent of women who were implanted with vaginal mesh suffered vaginal mesh erosion within only three months of implantation. As a result of numerous negative reports, the FDA issued a vaginal mesh warning to patients and physicians in 2011, cautioning that the risks of using vaginal mesh are so severe that alternative treatments should be considered. It is now widely accepted that, in most cases, pelvic organ prolapsed can be treated without the use of vaginal mesh

What are the vaginal Mesh complications ?

  • Erosion of vaginal tissue
  • infection
  • spot bleeding
  • pain during sex
  • lower back pain
  • pain on one side
  • depression
  • Hardening of the vaginal mesh
  • Infection
  • Pain and discomfort
  • Perforations of the bowel, bladder or blood vessels
  • Recurrence of Pelvic Organ Prolapse (POP) and Stress Urinary Incontinence (SUI)
  • Urinary problems
  • Vaginal mesh erosion
  • Vaginal scarring

Many women who have suffered injuries as a result of vaginal mesh have decided to file defective medical device lawsuits. This has become a middle district litigation and are being filed as MDl s are being filed. A product liability, multi district litigation lawyer can review your case. Ask questions and get answers. call our Transvaginal mesh support line today.

Doctors Investigating Faulty Medical Devices Suing FDA

Written by

FDA SUED BY ITS OWN DOCTORS AND SCIENTISTS

Whistleblowers accuse FDA of spying, persecution

03 February 2012

The US Food and Drug Administration (FDA) is being sued by its own scientists and doctors who allege they were spied on and persecuted by the agency for expressing safety concerns about the approval of medical devices. This legal action has prompted an investigation by a key lawmaker in the Senate.
It's claimed that the FDA installed spyware to monitor personal email accounts

Iowa Republican Senator Charles Grassley a powerful member of the judiciary committee that has jurisdiction over areas like civil liberties and constitutional law has asked FDA commissioner Margaret Hamburg to provide details about who authorised the monitoring of employees and why some of the plaintiffs are no longer employed by the agency. Hamburg has until 17 February to supply her answers.

In the lawsuit filed on 25 January, six whistleblowers claim that the FDA secretly spied on them for two years. They say that the agency began its campaign of electronic snooping after the agency learned that they had written a letter to the president elect, Barack Obama, and his transition team in early 2009 detailing misconduct in approving unsafe medical devices. In that letter, the plaintiffs called the FDA fundamentally broken , and said its scientific review process for medical devices has been corrupted and distorted by managers.
Soon after, the agency installed or activated spyware on the whistleblowers work computers and also monitored their private emails, according to court documents. In addition, evidence suggests that the FDA took screen shots of the employees computers and also intercepted their emails to and from staff members on key House and Senate oversight committees.
These actions appear to have continued even after the Office of Inspector General (OIG) at the FDA s parent agency the Department of Health and Human Services (HHS) denied the agency s request to take criminal or administrative action against the individuals. In a May 2010 letter to the FDA, the OIG concluded that the whistleblowers communications were legally protected.
Chilling effects
The plaintiffs, who were all heavily involved in the FDA s safety review process, are seeking an injunction to stop the agency from pursuing what they say is an illegal spying campaign. Two of these whistleblowers still work at FDA and say that they face continued harassment, two were fired and another two did not get their contracts renewed, according to Stephen Kohn, the lead attorney for the plaintiffs.
If you can target someone simply because they raise a legal, health or safety concern, that will have a chilling effect on any FDA employee alerting the public or Congress about matters of life and death, Kohn tells Chemistry World . There is a lot of pressure on these scientists to approve the devices.
According to Kohn, the whistleblowers raised major concerns about 20 medical devices that involve, among other things, ultrasound and CT scan technology. Specifically, these reviewers said some of the devices could expose patients to radiation at levels up to 800 times that of a chest x-ray and they found that others couldn t appropriately detect cancers. Nevertheless, Kohn says the FDA approved 19 out of 20 of these devices that had been flagged.
Whistleblowers point out fraud, waste and abuse when no one else will, and while they do so, while also risking their professional careers, they are often treated like skunks at a picnic, Grassley wrote in a 31 January letter to Hamburg, asserting that retaliation against whistleblowers should never be tolerated .
Grassley said that certain employees, including members of the Public Health Service Commissioned Corps within HHS, are not covered under the US Whistleblower Protection Act, which leaves them vulnerable to retaliation. He says that this is a one of several loopholes in current law that should to be closed.
The FDA said it can t comment on personnel issues or any matters subject to ongoing litigation.
Rebecca Trager

Pfizer, Zoloft Birth defect Lawyers, Zoloft Lawsuit Consolidation

Written by

Pfizer Zoloft Birth Defect Litigation Consolidation

Pfizer, the manufacturer of Zoloft, has filed a motion to consolidate all federal Zoloft birth defect lawsuits. Pfizer requested that they be centralized before one judge for pretrial litigation as part of a multidistrict litigation, or MDL.

On January 18, Pfizer asked the U.S. Judicial Panel on Multidistrict Litigation to create a Zoloft MDL in the U.S. District Court for the Southern District of New York.

Zoloft Birth Defect Lawsuits

A growing number of plaintiffs throughout the country have filed a Zoloft lawsuit against Pfizer, raising similar allegations that use of the antidepressant during pregnancy caused children to be born with a variety of severe birth defects and serious malformations.

New York Federal MDL

According to Pfizer, there are currently at least 59 lawsuits over Zoloft, which involve common claims and questions of fact. Furthermore, according to Pfizer, the Zoloft birth defect litigation should be consolidated to prevent conflicting pretrial rulings, reduce duplicative discovery and to serve the convenience of the parties, the witnesses and the federal court system.

Pfizer has proposed that the federal Zoloft cases should be centralized in New York, near the drug maker’s headquarters, which would provide a central location and easy access to the company’s records and important witnesses.

Pfizer has also offered the Northern and Southern Districts of Mississippi and the Nothern District of Ohio as possible alternate locations.

The majority of the complaints over Zoloft are currently pending in the U.S. District Court for the Eastern District of Pennsylvania, where at least 48 of lawsuits are pending.

Zoloft Indications

Zoloft (sertraline) was released by Pfizer in 1991 for the treatment of depression, obsessive-compulsive disorder and anxiety.

By 2007 there were nearly 30 million prescriptions, making it the most prescribed antidepressant in the United States. Zoloft belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRIs).

Zoloft Birth Defects

Recently, medical research and adverse event reports have suggested that use of Zoloft during pregnancy may increase the risk of serious and potentially life-threatening health problems for babies. These side effects include persistent pulmonary hypertension in newborns (PPHN), heart defects, lung defects, abdominal defects, cranial defects and other malformations.

Studies have suggested that Zoloft may increase the risk of birth defects when used as early as the first trimester of pregnancy, a time when many women do not even know they are pregnant.

The U.S. Judicial Panel on Multidistrict Litigation is expected to hear oral arguments on the motion during a hearing scheduled to occur on May 31, at the E. Barrett Prettyman U.S. Courthouse in Washington, D.C.

contact Free Legal Shield for a Zoloft lawyer today.

FDA Drug Warning for Acetaminophen for Infants

Written by

FDA Drug Safety Communication: Addition of another concentration of liquid acetaminophen marketed for infants

Safety Announcement
Additional Information for Patients
Additional Information for Healthcare Professionals
Additional Background Information

Safety Announcement

[12-22-2012] The U.S. Food and Drug Administration (FDA) is informing the public that an additional concentration of liquid acetaminophen marketed for "infants" (160 mg/5 mL) is now available at local stores. Until now, liquid acetaminophen marketed for infants was only available in 80 mg/0.8 mL or 80 mg/mL concentrations. This change in the concentration will affect the amount of liquid given to an infant, and should be especially noted if someone is accustomed to using the 80 mg /0.8 mL or 80 mg/mL concentrations of liquid acetaminophen.

Facts about OTC liquid acetaminophen marketed for "infants"

Used to temporarily reduce fever and relieve minor aches and pains due to the common cold, flu, headache, minor sore throat, and toothache.
Acetaminophen is marketed under brand names such as Tylenol, Little Fevers, Triaminic, Infant/Pain Reliever, Pedia Care, Triaminic Infants Syrup Fever Reducer Pain Reliever and other store brands (e.g., Rite Aid, CVS, Walgreens brand, etc.).
Consult your physician to dose for children under 2.

In addition to this change in concentration, this product may also be packaged with an oral syringe instead of a dropper.

To avoid confusion and the potential for dosing errors, consumers, parents, and caregivers should carefully read the Drug Facts label on the package to identify the concentration of the liquid acetaminophen (in mg/mL), dosage, and directions for use. Do not depend on banners stating it is a new product to identify different concentrations of liquid acetaminophen. Many products have similar banners.

It is also important to use the dosing device provided with the product in order to correctly measure the amount of liquid acetaminophen to be given. Patients and caregivers should contact their healthcare professional if they find the measuring device confusing or are unsure how to measure a dose for a child using the device provided.

Healthcare professionals should make sure to provide directions to patients that specify the concentration and dose of liquid acetaminophen that should be given to a child.

Infant Acetaminophen containers

Figure. Both boxes in this example say "New" on the front, but only one of them contains the new concentration of liquid acetaminophen. Always read the Drug Facts label and dosing instructions and use the measuring device that came with the product.

FDA has prepared a list of questions and answers and has issued a Consumer Update to provide an additional overview of these changes to OTC liquid acetaminophen marketed for infants.

Additional Information for Consumers and Parents/Caregivers

Parents and caregivers should always read the Drug Facts label on the package for the correct dosing, concentration, and directions for use.
If the dosing instructions provided by a healthcare provider differ from what is on the label, parents and caregivers should check with a healthcare professional before administering the medication.
The 160 mg/5 mL liquid acetaminophen marketed for infants may be packaged with an oral syringe instead of a dropper. Parents and caregivers should only use the device provided with the product purchased to measure the drug. Do not mix and match dosing devices.
Parents and caregivers should check with a healthcare professional if they have any questions about the concentration of liquid acetaminophen they have, dosing directions, or how to measure a dose using the dosing device provided with the product.
Consumers should report side effects or medication errors from the use of OTC acetaminophen products to the FDA MedWatch program using the information in the "Contact Us" box at the bottom of this page.

Additional Information for Healthcare Professionals

Another concentration (160 mg/5 ml) of liquid acetaminophen marketed for "infants" is now available in stores. This product is less concentrated than other liquid acetaminophen products marketed for infants. The other products currently available are in 80 mg/0.8 mL and 80 mg/1 mL concentrations.
Healthcare professionals should use their clinical judgment to recommend the most appropriate liquid acetaminophen product for children under the age of 12, and they should counsel caregivers on product differences.
The 160 mg/5 mL acetaminophen marketed for infants may be packaged with an oral syringe instead of a dropper. It is important to use only the dosing device provided with the product. Do not mix and match dosing devices.
The concentration of liquid acetaminophen should be included on a prescription because multiple products with different concentrations are available.
Healthcare professionals should report adverse events or medication errors involving OTC infant acetaminophen products to the FDA MedWatch program using the information in the "Contact Us" box at the bottom of this page.

Additional Background Information

On June 29-30, 2009, a joint meeting of the FDA Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee discussed the issue of over-the-counter (OTC) liquid acetaminophen (for complete safety reviews and background information discussed at this meeting, see the June 29-30, 2009 AC meeting material). A recommendation was made during this meeting to have only one concentration of pediatric liquid acetaminophen available OTC because products with different concentrations can cause dosing confusion among parents and caregivers that may lead to unintentional overdoses in pediatric patients.

Due to dosing errors t hat occurred with the concentrated acetaminophen formulation (80 mg/0.8 mL or 80 mg/mL), some manufacturers decided to voluntarily change their liquid acetaminophen products marketed for "infants" to the same concentration (160 mg/5 mL) of liquid acetaminophen products labeled for children. However, since this change is voluntary, products with the old concentration of acetaminophen marketed for infants are still available in stores and in medicine cabinets (see Table 1 below). The availability of infant acetaminophen 160mg/5mL began earlier this year.

Table 1. OTC Liquid Acetaminophen Concentration marketed for infants

Available in the Past Currently Available
80 mg/0.8 mL
(dropper) 80 mg/0.8 mL
(dropper)
80 mg/mL
(dropper) 80 mg/mL
(dropper)
160 mg/5 mL
(oral syringe)

Tylenol Lawyers accepting cases for liver damage from Tylenol overdose.

US Senators Demand More FDA Oversight On Depuy Hip Replacement

Written by

by Brian Devine on December 18, 2011

Following the massive DePuy hip replacement recall, Senators Charles Grassley (R-Iowa), Richard Blumenthal (D-Conn.) and Herb Kohl (D-Wis.) have introduced legislation to help protect patients from being exposed to dangerous medical devices and to ensure that recalls are conducted promptly when a company learns that a device is defective.

This bipartisan bill authorizes the FDA to require post-market clinical studies for medical devices such as hip implants, that could have serious safety risks. The bill also gives the FDA the ability to require manufacturers to conduct safety studies after a device is approved through the expedited 510(k) process, the regulatory loophole that allowed the DePuy ASR to be sold in the United States.

“This reform legislation should be part of the reauthorization of the medical device user fee law next year,” Grassley said. “The reforms incorporate well-founded recommendations from the Government Accountability Office and reflect the value of having a robust post-market surveillance operation in the FDA. Important information can be learned about product safety after a device is on the market, and when there are problems, the sooner the response, the better.”

“Unsafe medical devices pose severe dangers to patients and impede approval of new, safe devices – causing significant costs to our economy as well as health,” said Blumenthal. “This bill will help protect people from dangerous unsafe medical devices by demanding more consumer safeguards, improving recall management, avoiding costly recalls, and preventing irreversible injury to patients. By removing unsafe devices from the market more quickly and efficiently, we’re preserving a faster approval track for safe and effective products to reach patients.”

“Faulty medical devices, especially those implanted in the body, can have disastrous health impacts on patients,” Kohl said. “This legislation will help ensure that FDA can act quickly and decisively when there’s a problem, and that the drive toward getting new technologies to market won’t come at the risk of patient safety.”

The three Senators also sent investigative letters to five companies, including Johnson & Johnson / DePuy. The Senators have requested details about DePuy’s post-market surveilance of the ASR implant, and how and when it decided to recall the ASR from the market. The letter said:

As the Special Committee on Aging’s recent oversight hearing detailed, effective post-marketing surveillance practices allow companies to recognize problems with medical devices in a timely fashion, preventing expensive recalls later, and can also save lives and prevent unnecessary suffering.

FREE LEGAL SHIELD LAWYERS FOR DEPUY HIP IMPLANT RECALL INJURIES

Lawyers for the Depuy Hip Replacement are currently representing people nationwide who have had a DePuy ASR hip implant or a metal-on-metal Pinnacle hip implant that failed. If you or a loved one suffered an injury caused by a metal-on-metal hip implant, call 1 800 733-5342 innediatley to recover damages in a lawsuit against the manufacturer of the Depuy.

Orthopedic Error Malpractice

Written by

Orthopedic error lawyers are medical malpractice lawyers and product liability lawyers. Many of the lawsuits though to be malpractice are actually malfunctioning orthopedic devices. The manufacturers of these devices are liable. These are medical malpractice lawsuits against orthopedic doctors or surgeons.Orthopedic doctors and surgeons handle injuries related to bones, muscles, tendons, ligaments and nerves throughout the human body. Orthopedic physicians are responsible for many implant surgeries, diagnosing and operating on muscle tears, bone fractures, hip replacements and nerve damage. Given the scope of the orthopedic specialty, mistakes are bound to happen. While human errors are inevitable, patients usually are not responsible for these injuries, which can result in debilitating pain and suffering, financial loss, and even death. Orthopedic error Lawyers are medical malpractice lawyers who will see that your are compensated for your pain suffering or wrongful death of a loved one. Many Malfunctioning Orthopedic devices have injured unsuspectin victims and caused pain and suffering. These include various knee and hip replacement implants. The Depuy ASR as well as the Zimmer products have been at the center of many Product liability class action lawsuits.

Some of the common injuries which orthopedic error lawyers and medical malpractice lawyers litigate caused by orthopedic doctors or surgeons include:

  • The loss of a limb
  • Development of blood clots before or after surgery. If the clot travels to the lungs or brain, it can be fatal.
  • Complications from knee surgery
  • Complications from any arthroscopic surgery
  • Complications from knee or hip replacement
  • Blood vessel injury during surgery
  • Nerve vessel damage
  • Failure to diagnose or properly treat wrist or arm fractures causing serious injury
  • Failure to properly treat a neck fracture, causing serious injury
  • Failure to properly treat a hip fracture, causing serious injury or the need for a hip replacement
  • Failure to properly treat a spine fracture, causing serious injury, paralysis or paraplegia
  • Failure to diagnose any fracture as the result of misreading or failure to order an x-ray
  • Failure to fit a patient with appropriate screws or plates
  • Failure to treat inflammation or pain as a result of the healing and treatment process
  • Anesthesia-related injuries
  • Infection or sepsis
  • Decreased mobility

If you or a loved one has been the victim of orthopedic medical malpractice, you may be entitled to damages, including medical expenses, lost wages and other compensation. You should hire an orthopedic error lawyer, medical malpractice lawyer experienced in orthopedic surgeon or orthopedic doctor litigation. They will have the knowledge of these types of negligence and call in the appropriate expert witness . They will also be able to make sense of the orthopedic hospital and medical records as well as independent medical examiner evaluations